MIL-OSI: Data > Intelligence > News
Source: Tertiary Education Commission On this page: Final-year Fees Free entitlement is for the final year of the first provider-based qualification or work-based programme a learner completes from 1 January 2025, if that programme meets the qualification and programme eligibility criteria. Learners starting study or training for the first time on or after 1 January … Read more
Source: Tertiary Education Commission Last updated 21 May 2025 Last updated 21 May 2025 Print Share This page sets out the prior study and training criteria for final-year Fees Free learner eligibility. This page sets out the prior study and training criteria for final-year Fees Free learner eligibility. On this page: Prior study and training … Read more
Source: Tertiary Education Commission Last updated 21 May 2025 Last updated 21 May 2025 Print Share This page sets out the learner eligibility criteria for the final-year Fees Free policy. This page sets out the learner eligibility criteria for the final-year Fees Free policy. From 2025, to get Fees Free for the final year of … Read more
Source: Tertiary Education Commission Last updated 17 February 2025 Last updated 17 February 2025 Print Share This page provides information about transition to DXP Ngā Kete and changes to data requirements for Gateway-funded schools. This page provides information about transition to DXP Ngā Kete and changes to data requirements for Gateway-funded schools. What is DXP … Read more
Source: Tertiary Education Commission Last updated 12 November 2024 Last updated 12 November 2024 Print Share This page contains information about the data requirements for Other Fund Actuals data submission from 1 October 2024. This page contains information about the data requirements for Other Fund Actuals data submission from 1 October 2024. Other Fund Actuals … Read more
Source: PHARMAC Pharmac is consulting on a proposal to fund more medicines for melanoma, a type of skin cancer, from 1 June 2025. The medicines are: pembrolizumab (branded as Keytruda) for stage 3B or more advanced melanoma that can be removed by surgery dabrafenib (branded as Tafinlar) and trametinib (branded as Mekinist) for melanoma with … Read more
Source: PHARMAC Pharmac’s Board has begun the search for a new Chief Executive, advertising in New Zealand and overseas. Board Chair Paula Bennett says the Board is looking for a mix of strategic and operational leadership to help Pharmac become a more outward-focused, empathetic organisation. While recruitment is underway, Bennett says the Board has appointed … Read more
Source: PHARMAC Funding nivolumab in combination with ipilimumab for eligible people with kidney cancer We expect about 110 people with metastatic kidney cancer will benefit in the first year of funding. Both nivolumab and ipilimumab are immune checkpoint inhibitors. They work by helping the body’s immune system to fight cancer cells. The medicines are given … Read more
Source: PHARMAC Pharmac has decided to fund a new progestogen-only oral contraceptive pill called desogestrel (branded as Cerazette). Melissa Copland, Pharmac’s Clinical Lead–Medicines Management, says desogestrel will be funded for anyone who needs it from 1 April 2025. “Desogestrel is a progestogen-only contraceptive pill. It helps prevents pregnancy when taken within a 12-hour window each … Read more
Source: PHARMAC Pharmac Board Chair Paula Bennett is welcoming an independent report calling for stronger, more respectful relationships with consumers to ensure their voices are listened to and included in the organisation’s work. The report was prepared for the Board following two workshops with advocacy groups representing people with lived experience of health conditions. The … Read more
Source: PHARMAC Information on what the Pharmacology and Therapeutics Advisory Committee (PTAC) will be considering at its meeting in May 2025. Applications Foslevodopa / foscarbidopa for advanced Parkinson disease The Committee will discuss an application for a new treatment for advanced Parkinson disease for people experiencing severe motor fluctuations despite optimal treatment with other medicines. … Read more
Source: PHARMAC Pharmac is seeking feedback on a proposal to make it easier for people with asthma to access a type of inhaler. “We’re proposing two changes, which would make it easier for 120,000 New Zealanders with asthma to access the inhalers they need,” says Pharmac’s Director Pharmaceuticals, Geraldine MacGibbon. Pharmac is proposing to apply … Read more
Source: PHARMAC More New Zealanders will have access to medicines for blood cancers, bowel diseases, eczema and arthritis, following Pharmac’s decision to widen access to four medicines for six health conditions from 1 May 2025. The medicines and health conditions are: venetoclax (brand name Venclexta) in combination with azacitidine or cytarabine for a type of … Read more
Source: PHARMAC Pharmac is consulting on a proposal that would make it easier for thousands of New Zealanders to access contraceptives. Pharmac’s Clinical Lead – Medicines Management, Melissa Copland, says that the changes would improve access, and remove barriers for people who use IUDs. “The changes we are proposing would mean people would be able … Read more
Source: PHARMAC Pharmac is seeking feedback on a proposal to fund two brands of oestradiol patches for New Zealanders to use – Estradot, and Estradiol TDP Mylan. If approved, Pharmac would fund both brands of oestradiol patches from 1 December 2025 and people could use either brand of patch, subject to availability. The public consultation … Read more
Source: Media Outreach SINGAPORE – Media OutReach Newswire – 26 May 2025 – Woodfibre LNG, a subsidiary of Pacific Energy which is a member of the Royal Golden Eagle (RGE) group of companies, is setting a new benchmark for responsible natural gas export. At its new liquefied natural gas (LNG) facility under development in British … Read more
Source: Tertiary Education Commission Last updated 21 May 2025 Last updated 21 May 2025 Print Share The Minister for Vocational Education has announced the government’s decision to introduce an industry-led independent work-based learning model. The Minister for Vocational Education has announced the government’s decision to introduce an industry-led independent work-based learning model. The two key … Read more
Source: Tertiary Education Commission Last updated 21 May 2025 Last updated 21 May 2025 Print Share In December 2023, the Government announced its intention to disestablish Te Pūkenga | New Zealand Institute of Skills and Technology and Workforce Development Councils (WDCs). In December 2023, the Government announced its intention to disestablish Te Pūkenga | New … Read more
Source: Tertiary Education Commission Last updated 21 May 2025 Last updated 21 May 2025 Print Share This page provides information about the data required for reporting Work-based delivery (Actuals) on DXP Ngā Kete. This page provides information about the data required for reporting Work-based delivery (Actuals) on DXP Ngā Kete. MIL OSI
Source: Tertiary Education Commission On this page: Claiming Fees Free entitlement From 2026, after completing their first eligible provider-based qualification or work-based programme, learners will log in to myIR to confirm their eligibility (ie, if they meet the criteria), and claim their final-year Fees Free entitlement. Learners have 12 months to claim their entitlement once … Read more
Source: PHARMAC Pharmac is sharing the agenda for the upcoming Rare Disorders Advisory Committee meeting to be held on Tuesday 10 June 2025. Note the meeting date is now one day earlier than the date originally shared. This is to accommodate advisor availability. What we’re doing Pharmac is sharing what medicine applications will be considered … Read more
Source: PHARMAC An independent review has found that Pharmac needs to make significant organisational changes over the next five years to meet public and stakeholders’ expectations. Pharmac’s Board commissioned organisational expert Debbie Francis to undertake a review at the end of last year. Board Chair Paula Bennett has welcomed the review’s findings and thanked Pharmac … Read more
Source: PHARMAC Life was admin heavy “Life was just admin heavy. I was doing injections every day and testing my blood sugar at every meal, so I was ecstatic when I heard the news,” she says. “I think back to when I was 10, and my mum would wake me up two-to-three times every night … Read more
Source: PHARMAC Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its half-day meeting in May 2025. Correspondence and matters arising discussion papers Potential oncology agent brand changes The Committee will discuss potential product changes that may result from the 2024/2025 Invitation to Tender (ITT). This is seeking specific advice from … Read more
Source: New Zealand Film Commission The New Zealand Film Commission is offering up to 15 scholarships for industry practitioners who live in regional areas of Aotearoa, identify as deaf, disabled or neurodiverse (DDN), or identify as gender diverse to attend the 2025 Doc Edge Industry or Big Screen Symposium. MIL OSI
Source: New Zealand Film Commission The New Zealand Film Commission (NZFC) congratulates the outstanding achievements of the Māoriland Charitable Trust and Craig Gainsborough of Greenlit, recognised at the prestigious 2025 Global Production Awards, held in Cannes this week. The New Zealand Film Commission (NZFC) congratulates the outstanding achievements of the Māoriland Charitable Trust and Craig … Read more
Source: PHARMAC Pharmac is proposing a change to the Pharmaceutical Schedule rules, which if agreed, would give New Zealanders with cancer greater continuity of care. Pharmac is consulting on a proposal to amend the rules of the Pharmaceutical Schedule, following the Government’s decision to enable access to new publicly funded cancer medicines in private hospitals … Read more